Irving Institute Announces 2018-2019 Translational Therapeutics Accelerator Pilot Awardees
The Irving Institute for Clinical and Translational Research, home to Columbia University’s Clinical and Translational Science Award (CTSA) Program hub, announces the winners of the 2018-2019 Translational Therapeutics Accelerator pilot awards.
The Translational Therapeutics Accelerator (TRx) Pilot Award provides investigators with the resources to position their therapeutic discoveries for future commercial value. Awardees are expected to reach a value inflection point in their research. The pilot awardees are:
Lx6171: A New Therapeutic for the Highly Disabling Negative Symptoms of Schizophrenia
- Catherine Clelland, PhD, Pathology & Cell Biology
- James Clelland, PhD, Psychiatry (NYU)
Preclinical Optimization of DNA and mRNA-based Endotope Platforms
- Remi Creusot, PhD, Medicine
- Magdalena Bogun, MD, Medicine
Programmable Bacteria for Oral Delivery of Tumor-targeted Immunotherapy
- Tal Danino, PhD, Biomedical Engineering
- Nicholas Arpaia, PhD, Microbiology and Immunology
Inhaled Selective Serotonin Reuptake Inhibitor as a Treatment for COPD
- Jeanine D'Armiento, PhD, Medicine
- Adam Gerber, MD, PhD, Anesthesiology
Developing PI3 Kinase Inhibitors for T Cell Lymphoma
- Changchun Deng, MD, PhD, Medicine
- Jennifer K. Lue, MD, Medicine
Drug Based Modulation of Endogenous Fibrocartilage Stem Cells for TMJ Regeneration
- Mildred Embree, DMD, PhD, Dental Medicine
Validating OncoTreat, a Systems Biology Approach to Predict Drug Sensitivity, in Advanced Gastrointestinal Stromal Tumors
- Gary Schwartz, MD, Medicine
- Andrea Califano, PhD, Systems Biology
Development of a Novel Beta2-blocker for Treating Pancreatic Cancer
- Timothy C. Wang, MD, Medicine
- Donald Landry, MD, PhD, Chair, Medicine